CAPTORTX
Research CAPTORTX (CTX.WA) on Bullrun: market cap PLN 424.34M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCTX.WA
- ExchangeXWAR
- CountryPoland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyPLN
- Market capPLN 424.34M
- Financial periodQ1 2026
- RevenuePLN 328.00K
- Net income-PLN 11.38M
- Free cash flow-PLN 12.66M
- Gross margin100.0%
Valuation Snapshot
latest market cap is PLN 424.34M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | PLN 4.66M | -PLN 42.00M | -PLN 37.53M | 69.0% | n/a | PLN 10.72M | PLN 3.58M | PLN 23.48M |
| FY2022 | PLN 9.16M | -PLN 35.89M | n/a | 77.2% | -8240 | PLN 71.04M | n/a | PLN 96.32M |
| FY2021 | PLN 3.99M | -PLN 32.57M | n/a | 81.4% | -7480 | PLN 117.94M | n/a | PLN 124.20M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-10 | PLN 424.34M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 PLN.
About CAPTORTX
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, develops therapeutic molecules for treating oncological and autoimmune diseases in Poland. The company offers targeted protein degradation technology that utilizes the Optigrade drug discovery platform to overcome the limitations of inhibitors and antibody drugs by destroying disease-causing proteins that are resistant to available therapeutics.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is CAPTORTX's market cap?
CAPTORTX's market capitalization is PLN 424.34M.
What does CAPTORTX do?
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, develops therapeutic molecules for treating oncological and autoimmune diseases in Poland. The company offers targeted protein degradation technology that utilizes the Optigrade drug discovery platform to overcome the limitations of inhibitors and antibody drugs by destroying disease-causing proteins that are resistant to available therapeutics.